Latest Breaking News On - Krogsgaard - Page 1 : vimarsana.com

The Week That Perished

Infections in temporal proximity to HPV vaccination and adverse effects following vaccination in Denmark: A nationwide register-based cohort study and case-crossover analysis

Kanada schytala výprask od USA! Švýcaři jsou stoprocentní | Hokej.cz

PŘEHLED účastníků MS v hokeji - 2. část: Bělorusko, Velká Británie, Dánsko

V pátek 21. května začíná po roční odmlce způsobené pandemií koronaviru další, tentokrát již 85., ročník hokejového světového šampionátu, jenž se tentokráte uskuteční v lotyšské Rize. Server EuroZpávy.cz přichází před tímto prvním velkým sportovním svátkem tohoto sportovního roku s představením všech šestnácti účastnických mužstev, které se tohoto mistrovství zúčastní.

Novo Nordisk to start late-stage trial of semaglutide to treat Alzheimer's

By Reuters Staff 2 Min Read COPENHAGEN (Reuters) - Diabetes drugmaker Novo Nordisk will start a late-stage clinical trial to test its semaglutide drug as a treatment for early Alzheimer’s disease, it said on Wednesday. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen Novo shares were up 4.3% at 1418 GMT following the news. Sydbank analyst Soeren Loentoft described the move as a “good signal”, showing Novo’s confidence in the drug, but warned developing treatments for Alzheimer’s was notoriously difficult. “Many have tried without success in the last many years, so this is a high-risk study, and it is by no means certain that Novo’s semaglutide will have an effect,” he said.

Novo Nordisk moves semaglutide drug to phase 3 trial for Alzheimer's

By Syndicated Content Dec 16, 2020 7:23 AM COPENHAGEN (Reuters) – Diabetes drug manufacturer Novo Nordisk will initiate a late-stage trial to investigate the benefits of its semaglutide drug in treatment of Alzheimer’s disease, the company said on Wednesday. “Due to the growing unmet medical need and the increasing evidence of a potential therapeutic role for GLP-1, we will investigate the benefits of oral semaglutide in early Alzheimer’s disease,” Chief Scientific Officer Mads Krogsgaard said in a statement. The phase 3a trial is set to start in the first half of 2021 and include about 3,700 people, Novo said. (Reporting by Nikolaj Skydsgaard; Editing by David Goodman)